Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States
Journal of Managed Care & Specialty Pharmacy | September 30, 2023 | Volume: 29 | Issue: 11 | Pages: 1205-1218
10.18553/jmcp.2023.23031
| PMID 37776124